GLORIOSA
Trial Description:
Randomized, multicenter, open-label, phase 3 study of mirvetuximab
soravtansine in combination with bevacizumab versus bevacizumab alone as maintenance therapy for patients with FRĪ±-positive recurrent platinum-sensitive epithelial ovarian, fallopian tube, or primary peritoneal cancers who have not progressed after second-line platinum-based chemotherapy plus bevacizumab
Lead Cooperative Group:
Trial Number:
Disease Site:
Ovarian
Trial Status:
Recruiting
Contact person:
dlorusso